CCL5 and neoplasm: Heightened dual expression of the ligands for CCR5 and CXCR3 (CCL5 and CXCL9, respectively) positively correlates with the amount of tumor CD8a transcripts and patient survival in cancers of the ovary, breast, lung, colon, as well as melanoma (103).